April McClain Delaney visited Kite, a biopharmaceutical company ... asked the Kite staff questions about why the company, whose headquarters is in California, chose to have a location in Frederick ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Soligenix, Inc. (NASDAQ: SNGX) decreased in price early Tuesday, as the late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

Live webcasts of these presentations will be available in the Events and Presentations section of Olema's investor relations website at ir.olema.com . The webcasts will be archived for at least 30 ...

Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage ...

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private ...

Genelux Corporation’s GNLX share price has dipped by 10.63%, which has investors questioning if this is right time to buy.

Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet ... Vincerx is based in San Mateo, California, and has a research ...

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...